A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease [PDF]
The T cell Ig and mucin domain 3 (Tim-3) receptor has been implicated as a negative regulator of adaptive immune responses. We have utilized a proteomic strategy to identify novel proteins associated with graft versus host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT).
John Hansen +2 more
exaly +5 more sources
Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection [PDF]
: Soluble forms of the coinhibitory receptors programmed death 1 (PD-1) and Tim-3 exist, but their relationship with T-cell surface expression remains unclear. When measured by an enzyme-linked immunosorbent assay in plasma, soluble PD-1, and soluble Tim-3 were elevated during primary HIV infection, decreased on antiretroviral therapy to levels found ...
Genevieve Elizabeth Martin +2 more
exaly +7 more sources
The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells [PDF]
Acute myeloid leukemia (AML) is a severe and often fatal systemic malignancy. Malignant cells are capable of escaping host immune surveillance by inactivating cytotoxic lymphoid cells.
Jasmin Wellbrock +2 more
exaly +5 more sources
Serum soluble Tim‑3 is elevated in patients with cervical cancer and is higher in advanced clinical stages. [PDF]
T-cell immunoglobulin and mucin domain-containing protein-3 (Tim-3) is an immune checkpoint molecule that is expressed generally on the cell membrane of immune and cancer cells and is implicated as a negative regulator of anti-tumour immune responses; this occurs through the interaction of Tim-3 with galectin-9.
Conde-Rodríguez I +4 more
europepmc +3 more sources
Soluble TIM-3 and galectin-9 serve as additional diagnostic biomarkers in primary central nervous system lymphoma. [PDF]
Background: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive B-cell lymphoma in which early diagnosis remains challenging. Although cerebrospinal fluid (CSF) B-cell-associated factors including soluble interleukin-2 receptor subunit alpha (IL-2RA) are known diagnostic markers, they often reflect neuroinflammation and are ...
Nishii S +13 more
europepmc +4 more sources
Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
Osteosarcoma is the most frequent primary bone tumor that affects adolescents and children. However, diagnostic and prognostic biomarkers for osteosarcoma remain lacking. (Tim-3) T-cell immunoglobulin domain and mucin domain-3, which negatively regulates
Wenhui Ge +4 more
doaj +2 more sources
Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. [PDF]
Resistance to PD-1 blockade in onco-immunotherapy greatly limits its clinical application. T cell immunoglobulin and mucin domain containing-3 (Tim-3), a promising immune checkpoint target, is cleaved by ADAM10/17 to produce its soluble form (sTim-3) in humans, potentially becoming involved in anti-PD-1 resistance. Herein, serum sTim-3 upregulation was
Chen C +18 more
europepmc +3 more sources
Immunopathogenesis of severe pneumonia in children with emphasis on CD4+ T cells, Tim-3 and cytokine-mediated immune dysregulation [PDF]
Severe pneumonia in children remains a major cause of hospitalization, respiratory failure and infection-related mortality. Increasing evidence indicates that disease severity is shaped not only by pathogen burden but also by the timing, intensity and ...
Fang Cao, Qi Zhang, Lunan Yan
doaj +2 more sources
Plasma soluble TIM-3 is increased in normoglycemic South Asian women compared to Nordic women after gestational diabetes mellitus and associated with markers of metaflammation. [PDF]
Women with South Asian ethnicity have a higher risk of developing type 2 diabetes mellitus (T2DM) compared with white women of European descent, especially after gestational diabetes mellitus (GDM). Central obesity and adipose tissue dysfunction have been linked to their higher risk of T2DM, but the mechanisms are not known.
Grannes H +9 more
europepmc +4 more sources
Neoadjuvant chemotherapy (NAC) may alter the immune landscape of patients with early breast cancer (BC), potentially setting the scene for more effective implementation of checkpoint-targeted immunotherapy. This issue has been investigated in the current
Bernardo L. Rapoport +17 more
doaj +4 more sources

